| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10486419 | Value in Health | 2011 | 8 Pages |
Abstract
Tenofovir/emtricitabine was predicted to be more effective and cost-saving compared with abacavir/lamivudine and zidovudine/lamivudine in treatment-naïve adults with HIV-1 infection in the United States. © 2011, International Society for Pharmacoeconomics and Outcomes Research (ISPOR). All rights reserved.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Anita J. PhD, Sandra E. MSPH, Calvin MD, MSc,